← All trials
NCT04344951
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 6, 2020
- Primary completion
- Apr 1, 2021
- Completion date
- Apr 30, 2021
- First posted
- Apr 14, 2020
- Last posted
- Apr 14, 2020
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Unipharm, Inc.Lead sponsor
- Aristotle University of ThessalonikiCollaborator
- Athens General Hospital HippokrateioCollaborator
- Athens General Hospital HippokrateioOverall official - principal investigator
- General Hospital of Athens SismanoglioCollaborator
- General Hospital of Athens SismanoglioOverall official - principal investigator
- General State Hospital of CorfuCollaborator
- General State Hospital of CorfuOverall official - principal investigator
- Ioannina University HospitalCollaborator
- Ioannina University HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.